

# CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.

E-mail : concorddrugsltd@gmail.com

Website : www.concorddrugs.in

To,

Date: 14.08.2019

BSE Limited,  
P.J. Towers, Dalal Street,  
Mumbai- 400001

Dear Sir/Madam,

Sub: Outcome of Board meeting held on 14.08.2019

\*Ref: Scrip Code 538965

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Concord Drugs Limited held on Wednesday, 14.08.2019 at 5.00 p.m. at the registered office of the company, the following were considered and approved:

1. Approval of the unaudited financial results of the Company for the quarter ended 30.06.2019.
2. 24<sup>th</sup> Annual General Meeting of the Shareholders will be held on Monday, 30<sup>th</sup> day of September, 2019 at registered office of the company situated at Survey No.249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist-501511, Telangana,
3. Closure of the Register of Members and Share Transfer Books from Saturday, the 21<sup>st</sup> September, 2019 to Monday, 30<sup>th</sup> September, 2019 (both days inclusive).
4. E- Voting Period begins on 27.09.2019 from 9.00 a.m. and ends on 5.00 p.m. of 29.09.2019

The meeting concluded at 6:30 p.m.

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,  
For Concord Drugs Limited

*S. Nagi Reddy*  
S. Nagi Reddy  
Chairman  
DIN: 01764665



Encl: as above





# CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.

E-mail : concorddrugsltd@gmail.com Website : www.concorddrugs.in


STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 30TH JUNE 2019				
Particulars	Quarterly ended			
	30-Jun-19 (Unaudited)	31-Mar-19 (Audited)	30-Jun-18 (Unaudited)	31-Mar-19 (Audited)
<b>I Revenue from Operations</b>				
a. Net sales from Operations	1,331.07	1434.45	1,303.18	4,807.72
b. Other Operating Income				
	3.15	2.16	2.62	8.59
<b>II Other Income</b>				
	1,334.22	1436.61	1,305.80	4,816.31
<b>III Total Revenue (I+II)</b>				
<b>IV Expenses</b>				
a. Cost of Material Consumed	1,094.90	1342.94	1,104.58	3,913.85
b. Changes in inventories of finished goods, work-in-progress and stock-in-trade	21.30	(50.73)	91.22	45.59
c. Employees Benefit Expenses	81.36	34.15	52.72	252.92
d. Finance Costs	42.69	38.98	41.47	159.30
e. Depreciation and Amortisation expense	36.39	7.35	54.16	171.18
f. Other expenses	39.30	37.55	56.97	229.50
<b>Total Expenses</b>	<b>1,315.93</b>	<b>1410.23</b>	<b>1298.69</b>	<b>4772.33</b>
<b>Profit/ (Loss) before Exceptional item and tax (III-IV)</b>	<b>18.30</b>	<b>26.38</b>	<b>7.11</b>	<b>43.98</b>
<b>V Exceptional Items</b>				
	18.30	26.38	7.11	43.98
<b>VI Profit/ (Loss) before tax (V-VI)</b>				
<b>VII Tax Expense:</b>	<b>4.87</b>	<b>5.86</b>	<b>(5.66)</b>	<b>3.27</b>
<b>VIII a. Current tax</b>	<b>4.68</b>	<b>-3.50</b>	<b>1.45</b>	<b>11.72</b>
<b>b. Deferred tax charge/credit</b>	<b>0.19</b>	<b>9.36</b>	<b>7.11</b>	<b>8.44</b>
<b>IX Profit/ (Loss) for the period (VII-VIII)</b>	<b>13.43</b>	<b>20.52</b>	<b>12.78</b>	<b>40.70</b>
<b>X Other Comprehensive Income</b>				
Items that will not be reclassified to profit or loss				
<b>Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)</b>	<b>13.43</b>	<b>20.52</b>	<b>12.78</b>	<b>40.70</b>
<b>XI Paid-up equity share capital</b>	<b>874.38</b>	<b>786.18</b>	<b>786.18</b>	<b>786.18</b>
(Face value of the share- Rs. 10 each)				
<b>Other Equity</b>	<b>1,444.22</b>	<b>1,529.46</b>	<b>114.29</b>	<b>1,529.46</b>
<b>XII Earnings per share (of Rs. 10 each)</b>				
<b>XIII a. Basic (in Rs)</b>	<b>0.15</b>	<b>0.26</b>	<b>0.16</b>	<b>0.52</b>
<b>b. Diluted (in Rs)</b>	<b>0.15</b>	<b>0.26</b>	<b>0.16</b>	<b>0.52</b>

**Notes:**

- The financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under.
- The above standalone financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on August 14, 2019
- The figures of the quarter ended March 31, 2019 are the balancing figures between Audited figures in respect of the full financial year upto March 31, 2019 and the unaudited published year to date figures upto December 31, 2018, which were subjected to limited review by the statutory auditors.
- Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.
- The results are also available on the website of the Company www.concorddrugs.in.

Place: Hyderabad  
Date: 14-08-2018

By Order of the Board  
For Concord Drugs Limited  
S. Nagi Reddy  
Chairman  
DIN: 0176466







**Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**To the Board of Directors of Concord Drugs Limited,**

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Concord Drugs Limited ('the company') for the quarter ended 30 June 2019, being submitted by the Company pursuant to the requirements of the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
2. The statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the act'), SEBI circular CIR/CFD/FAC/62/2016, dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For N.G Rao and Associates  
Chartered Accountants  
FRN: 009399S**



**G Nageswara Rao  
(Partner)  
MNo: 207300**



**UDIN No: 19207300AAAACW8115**

**Place: Hyderabad  
Date: 14-08-2019**